Pfizer has agreed to acquire Metsera for an initial payment of $4.9 billion, with additional milestone payments potentially raising the total to $7.3 billion. This acquisition brings a diverse portfolio of obesity therapeutics including injectable and oral GLP-1 receptor agonists and related candidates, aiming to address treatment gaps in weight management. The deal comes after Pfizer's own internal obesity drug setbacks and positions the firm to become a major player in the burgeoning obesity drug market. Analysts see robust sales potential tied to Metsera's novel therapies. The transaction is expected to close by the end of 2025.